Cardium announces patent wins over Boston Scientific, Arch Development

By Elaine Rigoli

Tampa, Fla., March 29 - Cardium Therapeutics, Inc. announced winning patent decisions over Arch Development Corp. and Arch's licensee, Boston Scientific Corp., in proceedings conducted in the United States and Europe.

Following reviews by examiners and administrative patent judges, the claims being pursued by Arch and Boston Scientific have been declared unpatentable in Europe and also unpatentable in the United States, according to a news release.

"These key decisions represent important tests and confirmations of the strength of our intellectual property position, and the value of our methods for treating coronary heart disease, which we plan to advance to late-stage human clinical trials," said Tyler M. Dylan, Cardium chief business officer and general counsel, in a statement.

"We believe that our approach to treating angina by infusing angiogenic adenovectors to trigger the growth of new blood vessels in the heart represents a best-in-class technique," he added.

Natick, Mass.-based Boston Scientific is a developer, manufacturer and marketer of medical devices.

Chicago-based Arch Development is a venture capital fund with a focus on research-based technologies including biotechnology/life sciences and technology infrastructure.

Cardium, based in San Diego, is a medical technology company focused on the development of therapeutic products for the interventional cardiology market.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.